Literature DB >> 21423022

CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption.

George K Siberry1, Kunjal Patel, Russell B Van Dyke, Rohan Hazra, Sandra K Burchett, Stephen A Spector, Mary E Paul, Jennifer S Read, Andrew Wiznia, George R Seage.   

Abstract

OBJECTIVE: To assess the characteristics and outcomes of antiretroviral treatment (ART) interruption (TI) in perinatally HIV-infected children.
DESIGN: The Adolescent Master Protocol (AMP) of the Pediatric HIV/AIDS Cohort Study is a prospective cohort study that enrolled 7- to 16-year-old perinatally HIV-infected children between 2007 and 2009 from 15 sites in the United States and Puerto Rico.
METHODS: TI was defined as ART discontinuation for ≥ 3 months after ≥ 6 months of continuous ART. Subjects with and without TI were compared. Rates of change (slopes) in CD4 T-lymphocyte (CD4) count and percentage (%) per month during TI were calculated. Factors related to CD4 slope in univariable analyses were included in multivariable linear regression.
RESULTS: Of 444 eligible AMP subjects, 101 (23%) had at least one TI. Subjects with TI were born in earlier years but were otherwise similar to those without TI. For 81 TI subjects with complete data, the median (range) CD4% and CD4 count slopes were -0.66% per month (-3.54% to +1.34% per month) and -12.7 cells per cubic millimeter per month (-148 cells/mm to +31 cells/mm per month), respectively. On multivariable linear regression, there was a trend for lower CD4% slope to be associated (P < 0.1) with female sex, higher CD4% at TI, and higher peak viral load before TI. Advanced HIV disease stage and numerous ART regimens were more common in TI subjects in the lowest (fastest declining) CD4% slope quartile.
CONCLUSIONS: TIs in perinatally HIV-infected youth are common. During TIs, CD4 values decline on average but with high intersubject variability. Factors predicting CD4 slope during TI need further study.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21423022      PMCID: PMC3156860          DOI: 10.1097/QAI.0b013e318218e068

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

1.  Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57.

Authors:  Yanhua Tang; Sihong Huang; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; Elizabeth G Ryland; M Anne St John; Rohan Hazra; Celia D C Christie; Margaret E Feeney
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.

Authors:  Isabelle Pellegrin; Rodolphe Thiébaut; Patrick Blanco; Jean-François Viallard; Marie-Hélène Schrive; Patrick Merel; Geneviève Chêne; Hervé Fleury; Jean-François Moreau; Jean-Luc Pellegrin
Journal:  J Med Virol       Date:  2005-10       Impact factor: 2.327

3.  HIV infection presenting in older children and adolescents: a case series from Harare, Zimbabwe.

Authors:  Rashida A Ferrand; Ruedi Luethy; Filda Bwakura; Hilda Mujuru; Robert F Miller; Elizabeth L Corbett
Journal:  Clin Infect Dis       Date:  2007-02-01       Impact factor: 9.079

4.  Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort.

Authors:  Josiane Warszawski; Jérôme Lechenadec; Albert Faye; Catherine Dollfus; Ghislaine Firtion; Laurence Meyer; Danielle Douard; Fabrice Monpoux; Joëlle Tricoire; Yassine Benmebarek; Christine Rouzioux; Stéphane Blanche
Journal:  Clin Infect Dis       Date:  2007-08-14       Impact factor: 9.079

5.  Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

Authors:  W M El-Sadr; B Grund; J Neuhaus; A Babiker; C J Cohen; J Darbyshire; S Emery; J D Lundgren; A Phillips; J D Neaton
Journal:  Ann Intern Med       Date:  2008-09-02       Impact factor: 25.391

6.  Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection.

Authors:  Akihiko Saitoh; Marc Foca; Rolando M Viani; Susan Heffernan-Vacca; Florin Vaida; Jorge Lujan-Zilbermann; Patricia J Emmanuel; Jaime G Deville; Stephen A Spector
Journal:  Pediatrics       Date:  2008-03       Impact factor: 7.124

7.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

8.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

9.  Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.

Authors:  Giota Touloumi; Nikos Pantazis; Anna Antoniou; Heide A Stirnadel; Sarah A Walker; Kholoud Porter
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

10.  Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.

Authors:  Diana M Gibb; Trinh Duong; Veronica A Leclezio; A Sarah Walker; Gwenda Verweel; David T Dunn
Journal:  Pediatr Infect Dis J       Date:  2004-05       Impact factor: 2.129

View more
  13 in total

1.  Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Authors:  A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch
Journal:  HIV Med       Date:  2015-02-03       Impact factor: 3.180

2.  What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies.

Authors:  Gabriela Patten; Michael Schomaker; Mary-Ann Davies; Helena Rabie; Gert van Zyl; Karl Technau; Brian Eley; Andrew Boulle; Russell B Van Dyke; Kunjal Patel; Nosisa Sipambo; Robin Wood; Frank Tanser; Janet Giddy; Mark Cotton; James Nuttall; Gadija Essack; Brad Karalius; George Seage; Shobna Sawry; Matthias Egger; Lee Fairlie
Journal:  Pediatr Infect Dis J       Date:  2019-04       Impact factor: 2.129

3.  Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Kenneth Tapia; Evelyn Ngugi; Helen Moraa; Elizabeth Maleche-Obimbo; Vincent Otieno; Irene Inwani; Barbra A Richardson; Bhavna Chohan; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

4.  Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia.

Authors:  Adam W Bartlett; Pagakrong Lumbiganon; Nia Kurniati; Tavitiya Sudjaritruk; Thahira J Mohamed; Rawiwan Hansudewechakul; Penh S Ly; Khanh H Truong; Thanyawee Puthanakit; Lam V Nguyen; Kulkanya Chokephaibulkit; Viet C Do; Nagalingeswaran Kumarasamy; Nik Khairulddin Nik Yusoff; Moy S Fong; Dewi K Watu; Revathy Nallusamy; Annette H Sohn; Matthew G Law
Journal:  J Adolesc Health       Date:  2019-08-05       Impact factor: 5.012

5.  Salivary metabolite levels in perinatally HIV-infected youth with periodontal disease.

Authors:  Fabian Schulte; Oliver D King; Bruce J Paster; Anna-Barbara Moscicki; Tzy-Jyun Yao; Russell B Van Dyke; Caroline Shiboski; Mark Ryder; George Seage; Markus Hardt
Journal:  Metabolomics       Date:  2020-09-11       Impact factor: 4.290

6.  Brief Report: Youth Living With Perinatally Acquired HIV Have Lower Physical Activity Levels as They Age Compared With HIV-Exposed Uninfected Youth.

Authors:  Sahera Dirajlal-Fargo; Paige L Williams; Carly Broadwell; Elizabeth J McFarland; Kathleen M Powis; Denise L Jacobson; Jennifer Jao
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

7.  CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.

Authors:  Lee Fairlie; Brad Karalius; Kunjal Patel; Russell B van Dyke; Rohan Hazra; Miguel A Hernán; George K Siberry; George R Seage; Allison Agwu; Andrew Wiznia
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

Review 8.  Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents.

Authors:  Allison L Agwu; Lee Fairlie
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

9.  Following young people with perinatal HIV infection from adolescence into adulthood: the protocol for PHACS AMP Up, a prospective cohort study.

Authors:  Katherine Tassiopoulos; Kunjal Patel; Julie Alperen; Deborah Kacanek; Angela Ellis; Claire Berman; Susannah M Allison; Rohan Hazra; Emily Barr; Krystal Cantos; Suzanne Siminski; Michael Massagli; Jose Bauermeister; Danish Q Siddiqui; Ana Puga; Russell Van Dyke; George R Seage
Journal:  BMJ Open       Date:  2016-06-09       Impact factor: 2.692

10.  Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection.

Authors:  Masahiko Mori; Emily Adland; Paolo Paioni; Alice Swordy; Luisa Mori; Leana Laker; Maximilian Muenchhoff; Philippa C Matthews; Gareth Tudor-Williams; Nora Lavandier; Anriette van Zyl; Jacob Hurst; Bruce D Walker; Thumbi Ndung'u; Andrew Prendergast; Philip Goulder; Pieter Jooste
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.